Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Cardiometabolic risk high for schizophrenia patients

The risk for abdominal obesity may be increased as much as fourfold for patients with multi-episode schizophrenia compared with the rest of the population, reveal findings from a meta-analysis.

17 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

Men who didn't exercise more likely to have dysfunctional HDL

There's no question that high levels of good cholesterol-also known as high-density lipoprotein -seem to be protective against heart disease. Rather than depositing fat into the blood vessels the way the "bad" cholesterol (low-density lipoprotein does, HDL appears to carry cholesterol away from blood vessels to the liver. From there, the liver processes it for removal from the body.

13 Oct 2013

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

The U.S. Food and Drug Administration today approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis either before transplant, or after renal (kidney) transplantation in which there is recurrence of FSGS.

11 Oct 2013

High levels of HDL have been linked to increased breast cancer risks, enhance cancer aggressiveness

High levels of high density lipoprotein (HDL), also known as the "good cholesterol," are thought to protect against heart disease. However, what's good for one disease may not be good for another.

10 Oct 2013

Cholesterol-lowering drugs could be alternative treatment for people who take statins

A new class of cholesterol-lowering drugs that target a recently discovered regulator of harmful cholesterol could be an alternative or complementary treatment for the 30 million people who take statins, after the first trial in humans confirms the technique’s feasibility and safety.

4 Oct 2013

Statin medications pose no threat to short-term memory and may protect against dementia

A review of dozens of studies on the use of statin medications to prevent heart attacks shows that the commonly prescribed drugs pose no threat to short-term memory, and that they may even protect against dementia when taken for more than one year.

2 Oct 2013

Preoperative statin therapy improves results for isolated CABG and AVR operations

Patients receiving statin therapy before coronary artery bypass grafting (CABG) surgery appear to have a reduced risk of post-surgical mortality, stroke, and atrial fibrillation (irregular or rapid heart rate), according to an article in the October 2013 issue of The Annals of Thoracic Surgery.

1 Oct 2013

Scientists study genetic factors involved in complex diseases

Although heavily studied, the specific genetic causes of "complex diseases," a category of disorders which includes autism, diabetes and heart disease, are largely unknown due to byzantine genetic and environmental interactions.

27 Sep 2013

Research shows commonly prescribed statin medicines can adversely affect cognitive function

New research that looked at whether two commonly prescribed statin medicines, used to lower low-density lipoprotein (LDL) or 'bad cholesterol' levels in the blood, can adversely affect cognitive function has found that one of the drugs tested caused memory impairment in rats.

26 Sep 2013

Experimental agent fails to increase HDL levels, reveals new study

The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

5 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Study: Fixed-dose combination medication helps CVD patients

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Leisure-time physical activity might reduce risk of SCD among men with low CRF

Dr Laukkanen said: "Sudden cardiac death (SCD) accounts for approximately 50% of deaths from coronary heart disease. SCD typically occurs shortly after the onset of symptoms, leaving little time for effective medical interventions, and most cases occur outside hospital with few or no early warning signs. Finding ways to identify individuals at elevated risk of SCD would allow early interventions on risk factors to be implemented."

2 Sep 2013

Aortic stenosis doubles in patients with family history of the condition

Aortic stenosis is the most common heart valve disease in the elderly. It is associated with congenital bicuspid aortic valve and previous rheumatic heart disease, but is also often caused by calcification of a normal valve. Calcification of a normal valve may be associated with atherosclerotic changes in the portion of the aorta closest to the valve.

2 Sep 2013

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Dezima Pharma, the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the initiation of a double blind, placebo controlled, Phase 2b dose ranging study of DEZ-001 (previously TA-8995), alone and in combination with statins, in order to study the effects on a wide range of lipids and other biomarkers of cardiovascular disease in patients with mild dyslipidemia.

30 Aug 2013

Study suggests evaluations of ACO programs may need to consider patient utilization of clinical, economic benefits

Payment incentives implemented with a commercial accountable care organization (ACO) initiative in Massachusetts -Blue Cross Blue Shield's Alternative Quality Contract (AQC) - were associated with lower spending for Medicare enrollees served by the provider groups participating in the AQC, findings that suggest that evaluations of ACO programs may need to consider the implications for other patient populations to assess their full clinical and economic benefits, according to a study in the August 28 issue of JAMA.

29 Aug 2013

Inflammatory status upregulated in first-episode schizophrenia

Patients with first-episode schizophrenia exhibit upregulation of key proinflammatory molecules, study findings show.

28 Aug 2013

Clinical trial to study benefits of statins in prevention of heart attacks and strokes

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, recently published a commentary in the American Journal of Medicine, about the benefits of statins in the prevention of heart attacks and strokes in subjects previously thought at too low a risk to be treated.

28 Aug 2013

Lipoprotein News and Research

Further Reading

Cardiometabolic risk high for schizophrenia patients

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Men who didn't exercise more likely to have dysfunctional HDL

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

High levels of HDL have been linked to increased breast cancer risks, enhance cancer aggressiveness

Cholesterol-lowering drugs could be alternative treatment for people who take statins

Statin medications pose no threat to short-term memory and may protect against dementia

Preoperative statin therapy improves results for isolated CABG and AVR operations

Scientists study genetic factors involved in complex diseases

Research shows commonly prescribed statin medicines can adversely affect cognitive function

Experimental agent fails to increase HDL levels, reveals new study

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Study: Fixed-dose combination medication helps CVD patients

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Leisure-time physical activity might reduce risk of SCD among men with low CRF

Aortic stenosis doubles in patients with family history of the condition

Dezima starts DEZ-001 Phase 2b study in patients with mild dyslipidemia

Study suggests evaluations of ACO programs may need to consider patient utilization of clinical, economic benefits

Inflammatory status upregulated in first-episode schizophrenia

Clinical trial to study benefits of statins in prevention of heart attacks and strokes

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics